For over three decades the role of aspirin in reducing colorectal cancer risk has been explored in a number of settings; in particular, for high-risk patients with FAP (Waddell and Loughry, 1983; Giardiello et al, 1993), HNPCC (Burn et al, 2011), patients already treated for colorectal adenomas (Baron et al, 2003), and for colorectal carcinomas (Rothwell et al, 2012). The gene discussed is FAP; the disease is colorectal carcinoma.